<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-11-02-2026-shutterstock_1116008312-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-11-02-2026-shutterstock_1116008312-430x241.jpg"/></p>
<p>此次合作將結合 Insilico Medicine 在小分子設計、候選分子篩選和靶點識別方面的技術。來源：tilialucida / Shutterstock.com。</p>
<p>Insilico Medicine 已與中國醫療系統（CMS）在中樞神經系統（CNS）和自身免疫疾病的多個項目上宣佈了幾項人工智能藥物發現合作。</p>
<p>兩家公司計劃共同開發至少兩個研發項目，利用 Insilico Medicine 的人工智能平台以及 CMS 在臨牀開發方面的專業知識。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Alaunos Therapeutics Inc 的基因修飾細胞療法針對...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Bristol-Myers Squibb Co 的 BMS-90011</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>根據協議，Insilico Medicine 將為每個項目獲得研發資金。</p>
<p>此次合作將結合 Insilico Medicine 的 Pharma.AI 平台和小分子設計、候選分子篩選及靶點識別技術，以及 CMS 在監管規劃、臨牀試驗和商業化方面的經驗。</p>
<p>雙方旨在覆蓋從早期發現到將新療法推向市場的整個價值鏈。</p>
<p>項目團隊將共同優化決策，旨在縮短開發週期並提高臨牀成功率。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報</p>
<p>CMS 董事長、首席執行官、總裁兼執行董事 LAM Kong 表示：“我們將繼續豐富我們的產品線，擁有全球首創（FIC）和最佳（BIC）創新資產，高效推進其臨牀研究、開發和商業化，推動科學成就持續轉化為臨牀實踐。”</p>
<p>Insilico Medicine 和 CMS 打算整合各自的資源和專業知識，加速實驗室發現轉化為臨牀開發，最終為患者提供更多治療方案。</p>
<p>Insilico Medicine 聯合首席執行官兼首席科學官 Feng Ren 表示：“在這一合作框架下，我們期待利用資源共享和聯合決策，顯著縮短高潛力創新藥物的開發週期，提高轉化效率和臨牀成功率，加速更多創新分子從 ‘概念驗證’ 到真正 ‘惠及患者’ 的旅程。</p>
<p>“展望未來，雙方將繼續在產品線佈局、臨牀策略和全球合作方面深化多維度合作，進一步提高創新藥物的可及性，為患者提供更多差異化的治療選擇。”</p>
<p>上個月，Insilico 與 Servier 達成了一項價值高達 8.88 億美元的多年研發合作，以開發和發現新的腫瘤治療方案。</p>

康哲藥業

<p>Insilico Medicine 與中國醫療系統（CMS）達成合作，啓動針對中樞神經系統（CNS）和自身免疫疾病的人工智能藥物發現合作。此次合作將利用 Insilico 的 Pharma.AI 平台進行小分子設計和候選藥物篩選，並結合 CMS 在臨牀開發方面的專業知識。Insilico 將為每個項目獲得研發資金，旨在簡化藥物開發流程並提高臨牀成功率。兩家公司計劃在臨牀戰略和全球合作伙伴關係方面加深合作，以改善患者獲得創新治療的機會</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-11-02-2026-shutterstock_1116008312-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-11-02-2026-shutterstock_1116008312-430x241.jpg"/></p>
<p>The collaboration will combine Insilico Medicine’s technologies for small-molecule design, candidate molecules screening, and target identification. Credit: tilialucida / Shutterstock.com.</p>
<div class="lb-trans"><p>此次合作將結合 Insilico Medicine 在小分子設計、候選分子篩選和靶點識別方面的技術。來源：tilialucida / Shutterstock.com。</p>
</div><p>Insilico Medicine has announced several AI drug discovery collaborations with China Medical System (CMS) across several projects in central nervous system (CNS) and autoimmune diseases.</p>
<div class="lb-trans"><p>Insilico Medicine 已與中國醫療系統（CMS）在中樞神經系統（CNS）和自身免疫疾病的多個項目上宣佈了幾項人工智能藥物發現合作。</p>
</div><p>The companies plan to jointly develop at least two research and development (R&amp;D) programmes using Insilico Medicine’s AI platform alongside CMS’ expertise in clinical development.</p>
<div class="lb-trans"><p>兩家公司計劃共同開發至少兩個研發項目，利用 Insilico Medicine 的人工智能平台以及 CMS 在臨牀開發方面的專業知識。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Alaunos Therapeutics Inc's Gene-Modified Cell Therapy to Targ...</h4>
<div class="lb-trans"><h4>NPVM: Alaunos Therapeutics Inc 的基因修飾細胞療法針對...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Bristol-Myers Squibb Co's BMS-90011</h4>
<div class="lb-trans"><h4>NPVM: Bristol-Myers Squibb Co 的 BMS-90011</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Under the agreement, Insilico Medicine will receive R&amp;D funding for each programme.</p>
<div class="lb-trans"><p>根據協議，Insilico Medicine 將為每個項目獲得研發資金。</p>
</div><p>The collaboration will combine Insilico Medicine’s Pharma.AI platform and technologies for small-molecule design, candidate molecules screening, and target identification with CMS’s experience in regulatory planning, clinical trials, and commercialisation.</p>
<div class="lb-trans"><p>此次合作將結合 Insilico Medicine 的 Pharma.AI 平台和小分子設計、候選分子篩選及靶點識別技術，以及 CMS 在監管規劃、臨牀試驗和商業化方面的經驗。</p>
</div><p>Both entities aim to cover the entire value chain from early discovery to bringing new therapies to market.</p>
<div class="lb-trans"><p>雙方旨在覆蓋從早期發現到將新療法推向市場的整個價值鏈。</p>
</div><p>Project teams will jointly optimise decision-making, aiming to shorten development timelines and improve clinical success rates.</p>
<div class="lb-trans"><p>項目團隊將共同優化決策，旨在縮短開發週期並提高臨牀成功率。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>CMS chairman, CEO, president and executive director LAM Kong said: “We continue to enrich our pipeline with global first-in-class (FIC) and best-in-class (BIC) innovative assets, efficiently advancing their clinical research, development, and commercialisation to empower the continuous translation of scientific achievements into clinical practice.”</p>
<div class="lb-trans"><p>CMS 董事長、首席執行官、總裁兼執行董事 LAM Kong 表示：“我們將繼續豐富我們的產品線，擁有全球首創（FIC）和最佳（BIC）創新資產，高效推進其臨牀研究、開發和商業化，推動科學成就持續轉化為臨牀實踐。”</p>
</div><p>Insilico Medicine and CMS intend to integrate their resources and expertise to accelerate laboratory discoveries into clinical development, ultimately providing more treatments for patients.</p>
<div class="lb-trans"><p>Insilico Medicine 和 CMS 打算整合各自的資源和專業知識，加速實驗室發現轉化為臨牀開發，最終為患者提供更多治療方案。</p>
</div><p>Insilico Medicine co-CEO and chief scientific officer Feng Ren said: “Under this collaboration framework, we look forward to leveraging resource sharing and joint decision making to significantly shorten the development cycle of high-potential innovative drugs, enhance translational efficiency and clinical success rates, and accelerate the journey of more innovative molecules from ‘proof of concept’ to truly ‘benefiting patients’.</p>
<div class="lb-trans"><p>Insilico Medicine 聯合首席執行官兼首席科學官 Feng Ren 表示：“在這一合作框架下，我們期待利用資源共享和聯合決策，顯著縮短高潛力創新藥物的開發週期，提高轉化效率和臨牀成功率，加速更多創新分子從 ‘概念驗證’ 到真正 ‘惠及患者’ 的旅程。</p>
</div><p>“Going forward, the two parties will continue to deepen multi-dimensional collaboration in pipeline layout, clinical strategy, and global partnerships, further improving the accessibility of innovative medicines, providing patients with more differentiated treatment options.”</p>
<div class="lb-trans"><p>“展望未來，雙方將繼續在產品線佈局、臨牀策略和全球合作方面深化多維度合作，進一步提高創新藥物的可及性，為患者提供更多差異化的治療選擇。”</p>
</div><p>Last month, Insilico entered a multi-year R&amp;D collaboration with Servier, worth up to $888m, to develop and discover new oncology therapies.</p>
<div class="lb-trans"><p>上個月，Insilico 與 Servier 達成了一項價值高達 8.88 億美元的多年研發合作，以開發和發現新的腫瘤治療方案。</p>
</div>

Insilico 與康哲藥業啓動針對中樞神經系統疾病的藥物研發合作